Pretreatment serum interleukin-1 ???2 , interleukin-6, and tumor necrosis factor- ???± levels predict the progression of colorectal cancer

摘要

Abstract The correlations of pretreatment serum concentrations of proinflammatory cytokines such as interleukin (IL)-1 ???2 , IL-6, and tumor necrosis factor- ???± (TNF ???± ) with the clinicopathologic features and progression of colorectal cancer (CRC) were investigated. The pretreatment serum levels of IL-1 ???2 , IL-6, and TNF ???± were measured in 164 CRC patients before treatment. The relationships between changes in proinflammatory cytokine and C-reactive protein (CRP) levels and both clinicopathologic variables and disease progression were examined by univariate and multivariate analysis. Advanced tumor stage was associated with a poorer histologic differentiation, higher CRP level, lower albumin level, and inferior progression-free survival rate (PFSR). Furthermore, high levels of CRP (>5 mg/L) were associated with proinflammatory cytokine intensity, defined according to the number of proinflammatory cytokines with levels above the median level (IL-1 ???2 ?￠???￥10 pg/mL; IL-6 ?￠???￥ 10 pg/mL; and TNF ???± ?￠???￥55 pg/mL). Under different inflammation states, proinflammatory cytokine intensity, in addition to tumor stage, independently predicted PFSR in patients with CRP <5 mg/L, whereas tumor stage was the only independent predictor of PFSR in patients with CRP ?￠???￥5 mg/L. Proinflammatory cytokine intensity and the CRP level are clinically relevant for CRC progression. Measurement of IL-1 ???2 , IL-6, and TNF ???± serum levels may help identify early cancer progression among patients with CRP <5 mg/L in routine practice.